Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer

Background/Aim: To explore the prognostic value of lower urinary tract symptoms (LUTS) in patients with newly diagnosed regional lymph node-positive prostate cancer. Patients and Methods: The prognostic value of LUTS for progression-free (PFS) and overall (OS) survival, as well as the differential prognostic impact of radiotherapy by LUTS was investigated. Results: Univariate Cox-model analysis showed a statistically significantly increased hazard risk for PFS and OS for men with International Prostate Symptom Score (IPSS)≥19 and Overactive Bladder Symptom Score (OABSS) ≥8 at diagnosis. Patients with lower IPSS had a better PFS at 5 years (70.0% vs. 51.9%, p=0.027) and OS at 5 year (89.3% vs. 73.6%, p=0.016). Similarly, a lower OABSS was associated with greater PFS at 5 years (67.4% vs. 23.4%, p<0.001) and OS at 5 years (85.3% vs. 57.1%, p=0.012). Conclusion: IPSS and OABSS were prognostic for PFS and OS in patients with regional lymph node-metastatic prostate cancer.

[1]  H. G. van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2020, European urology.

[2]  Y. Shioyama,et al.  The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation? , 2020, Urologic oncology.

[3]  P. Kantoff,et al.  Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. , 2020, European urology.

[4]  A. D'Amico,et al.  Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  Ronald C. Chen,et al.  A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. , 2019, European urology oncology.

[6]  A. Amini,et al.  Node-positive Nonmetastatic Prostate Cancer: Time to Reconsider Prognostic Staging? , 2019, European urology.

[7]  K. Kuroiwa,et al.  Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study , 2019, Medical Oncology.

[8]  D. Roder,et al.  Prostate cancer outcomes for men who present with symptoms at diagnosis , 2017, BJU international.

[9]  M. Parmar,et al.  Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. , 2016, JAMA oncology.

[10]  G. Giles,et al.  Increased prostate cancer specific mortality following radical prostatectomy in men presenting with voiding symptoms—A whole of population study , 2015, Prostate international.

[11]  J. Patard,et al.  Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome. , 2015, Urologic oncology.

[12]  A. Jemal,et al.  Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. , 2015, Journal of the National Cancer Institute.

[13]  K. Kihara,et al.  Impact of lower urinary tract symptoms on prostate cancer risk among Japanese men with prostate‐specific antigen <10 ng/mL and non‐suspicious digital rectal examination , 2013, International journal of urology : official journal of the Japanese Urological Association.

[14]  J. Tward,et al.  Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. , 2013, Practical radiation oncology.

[15]  J. Oh,et al.  Is there any association between the severity of lower urinary tract symptoms and the risk of biopsy‐detectable prostate cancer in patients with PSA level below 20 ng/ml in multi‐core prostate biopsy? , 2013, The Prostate.

[16]  Dae Hun Lee,et al.  Are Men Who Undergo Radical Prostatectomy with Lower Urinary Tract Symptoms at an Increased Risk for Aggressive Prostate Cancer? , 2011, Korean journal of urology.

[17]  M. Borre.  Screening by lower urinary tract symptoms vs asymptomatic prostate‐specific antigen levels leading to radical prostatectomy in Danish men: tumour characteristics and treatment outcome , 2009, BJU international.

[18]  L. Vatten,et al.  Lower urinary tract symptoms and risk of prostate cancer: The HUNT 2 Cohort, Norway , 2008, International journal of cancer.

[19]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Y. Homma,et al.  Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. , 2006, Urology.

[21]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[22]  D. Sharp,et al.  Symptomatic diagnosis of prostate cancer in primary care: a structured review. , 2004, The British journal of general practice : the journal of the Royal College of General Practitioners.

[23]  David C. Miller,et al.  Prostate carcinoma presentation, diagnosis, and staging , 2003, Cancer.

[24]  L. Sobin,et al.  TNM classification of malignant tumors, fifth edition (1997) , 1997, Cancer.

[25]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[26]  H. Chandler.  Data Base , 1985, Journal of learning disabilities.

[27]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[28]  B. Davis,et al.  Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy. , 2016, European urology.

[29]  O. Beahrs.  The American Joint Committee on Cancer. , 1984, Bulletin of the American College of Surgeons.